Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

0.5820 -0.0420 (-6.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
Spero Therapeutics's Earnings Outlook
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for another dive into the biggest pre-market stock movers with all the hot topics traders need to know about on Friday! 
Via InvestorPlace
Spero Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Outlook For Spero Therapeutics
Via Benzinga
Earnings Scheduled For March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
Via Benzinga
Earnings Outlook For Spero Therapeutics
Spero Therapeutics (NASDAQ:SPRO) is set to give its latest quarterly earnings report on Monday, 2022-11-14. Here's what investors need to know before the announcement. Analysts estimate that Spero... 
Via Benzinga
How Is The Market Feeling About Spero Therapeutics?
Spero Therapeutics's (NASDAQ:SPRO) short percent of float has risen 180.65% since its last report. The company recently reported that it has 777 thousand shares sold short, which is 2.61% of all... 
Via Benzinga
EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike
UBS cut Lyft, Inc. (NASDAQ: LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading. 
Via Benzinga
Short Volatility Alert: Spero Therapeutics, Inc.
On Thursday, shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) experienced volatile short activity. After the activity, the stock price went up +168.29% to $2.20. The overall sentiment for SPRO has... 
Via Benzinga
Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce
Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero... 
Via Benzinga
Dow Turns Higher; Crude Oil Rises 0.7%
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Stocks Keep Sinking As Wall Street Comes To Terms With Fed Hike
Stocks are sinking even lower on Thursday, erasing their muted morning gains to resume yesterday's late-session selloff, which was sparked by yet another rate hike from the U.S. Federal Reserve. 
Via Talk Markets
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr
Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Exposures Product Safety
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. 
Via Benzinga
How Is The Market Feeling About Spero Therapeutics?
Spero Therapeutics's (NASDAQ:SPRO) short percent of float has fallen 32.61% since its last report. The company recently reported that it has 275 thousand shares sold short, which is 0.93% of all... 
Via Benzinga
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
 Gainers 
Via Benzinga
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK). 
Via InvestorPlace
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..
Reuters 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement. 
Via InvestorPlace
US Stocks Could Remain Jittery Thursday Over Fed Rate Hike As S&P 500, Nasdaq Futures See Volatility — McDonald's In Focus
The major U.S. index futures are flatlining, as traders are digesting the implication of the Fed's policy statement and a couple of interest rate decisions from Japan and the United Kingdom. 
Via Benzinga
Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic
GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr.  
Via Benzinga
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem... 
Via Benzinga
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.